Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CollPlant Biotechnologies LtdCLGN · Entity 8153 | Director | March 18, 2026 | March 18, 2026 |
| NEPHROS INCNEPH · Entity 7279 | Director | January 01, 2025 | January 03, 2025 |
| RVL Pharmaceuticals plcRVLP · Entity 108806 | Director | August 10, 2023 | August 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CollPlant Biotechnologies Ltd
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Share UnitsSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 10,000 F1: Of the restricted share units reported herein, 3,125 units are vested, and the remaining 6,875 units vest in eleven equal quarterly installments beginning March 25, 2026 and ending September 25, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date. |
| Options to Purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $6.39 · Expires 2032-05-02 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: 44,062 options are fully vested and exercisable and the remaining 2,938 vest is May 2, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Of the restricted share units reported herein, 3,125 units are vested, and the remaining 6,875 units vest in eleven equal quarterly installments beginning March 25, 2026 and ending September 25, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
F2: 44,062 options are fully vested and exercisable and the remaining 2,938 vest is May 2, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
NEPHROS INC
Report date January 01, 2025 · Filed January 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.47 · Expires 2035-01-01 | Direct | 7,050 |
Reported balance
After 2025-01-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-01-01 · Grant · Acquired 7,050 · Balance 7,050 F4: Represents options granted to the reporting person for her service on the Company's Board of Directors for 2024. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.22 · Expires 2029-02-08 | Direct | 9,617 |
Reported balance
Holding disclosure · report date 2025-01-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 9,617 F1: Fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.57 · Expires 2029-12-16 | Direct | 5,568 |
Reported balance
Holding disclosure · report date 2025-01-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 5,568 F1: Fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.06 · Expires 2031-01-06 | Direct | 6,850 |
Reported balance
Holding disclosure · report date 2025-01-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 6,850 F1: Fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.82 · Expires 2031-12-14 | Direct | 7,062 |
Reported balance
Holding disclosure · report date 2025-01-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 7,062 F1: Fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.07 · Expires 2033-01-05 | Direct | 7,080 |
Reported balance
Holding disclosure · report date 2025-01-01 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 7,080 F2: This option vests as to 2,360 shares on each of 1/5/23, 1/5/24 and 1/5/25. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2034-05-14 | Direct | 7,323 |
Reported balance
Holding disclosure · report date 2025-01-01 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 7,323 F3: This option vests as to 2,441 shares on each of 5/14/24, 5/14/25 and 5/14/26. |
| Common StockSEC Table I · non-derivative | Direct | 48,629 |
Reported balance
Holding disclosure · report date 2025-01-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 48,629 |
Filing footnotes · ownership attribution and instrument terms
F1: Fully exercisable.
F2: This option vests as to 2,360 shares on each of 1/5/23, 1/5/24 and 1/5/25.
F3: This option vests as to 2,441 shares on each of 5/14/24, 5/14/25 and 5/14/26.
F4: Represents options granted to the reporting person for her service on the Company's Board of Directors for 2024. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27.
RVL Pharmaceuticals plc
Report date August 10, 2023 · Filed August 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 112,557 |
Reported balance
After 2023-08-10 transaction · row 1
1 source rowRow 1 · 2023-08-10 · Tax withholding · Disposed 12,000 · Balance 112,557 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2025 Filed Jan 3, 2025 22:08 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (right to buy) · Derivative | 7,050 | $0.00 Strike: $1.47 | $0.00 |
DisclosureSEC source: 0001062993-25-000236 · form4.xml · derivative · entry 8 Lask Alisa · CIK 0001767593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,050 Underlying: Common Stock · 7,050 shares Expires 2035-01-01 F4 · derivative.exercise_date: Represents options granted to the reporting person for her service on the Company's Board of Directors for 2024. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:26 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (right to buy) · Derivative | 7,323 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001062993-24-010455 · form4.xml · derivative · entry 7 Lask Alisa · CIK 0001767593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,323 Underlying: Common Stock · 7,323 shares Expires 2034-05-14 F3 · derivative.exercise_date: Represents options granted to the reporting person for her service on the Company's Board of Directors for 2023. This option vests as to 2,441 shares on each of 5/14/24, 5/14/25 and 5/14/26. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 21:48 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 9,291 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022644 · form4.xml · nonDerivative · entry 1 Lask Alisa · CIK 0001767593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,629 F1 · shares: Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for her service on the Company's Board of Directors for 2023. These shares of restricted stock vest 6 months following the grant date. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 17:35 UTC | RVL Pharmaceuticals plc RVLP · Entity 108806 | Tax withholdingOrdinary Shares | 12,000 | $0.49 | $5,880.00 |
DisclosureSEC source: 0001104659-23-091548 · tm2323760-1_4seq1.xml · nonDerivative · entry 1 Lask Alisa · CIK 0001767593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,557 Read SEC document |
| July 05, 2023 Filed Jul 11, 2023 21:15 UTC | RVL Pharmaceuticals plc RVLP · Entity 108806 | GrantOrdinary Shares | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-080116 · tm2321087-1_4seq1.xml · nonDerivative · entry 1 Lask Alisa · CIK 0001767593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,557 F1 · kind: Represents a grant of restricted stock units. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:33 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (right to buy) · Derivative | 7,080 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001062993-23-000721 · form4.xml · derivative · entry 6 Lask Alisa · CIK 0001767593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,080 Underlying: Common Stock · 7,080 shares Expires 2033-01-05 F4 · derivative.exercise_date: Represents options granted to the reporting person for her service on the Company's Board of Directors for 2022. This option vests as to 2,360 shares on each of 1/5/23, 1/5/24 and 1/5/25. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:33 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 27,613 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-000721 · form4.xml · nonDerivative · entry 1 Lask Alisa · CIK 0001767593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,338 F1 · shares: Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for her service on the Company's Board of Directors for 2022. These shares of restricted stock vest 6 months following the grant date. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 16:07 UTC | RVL Pharmaceuticals plc RVLP · Entity 108806 | GrantOrdinary Shares | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-090049 · tm2222999-7_4seq1.xml · nonDerivative · entry 1 Lask Alisa · CIK 0001767593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,557 F1 · kind: Represents a grant of restricted stock units. Read SEC document |
| December 14, 2021 Filed Dec 17, 2021 02:17 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (right to buy) · Derivative | 7,062 | $0.00 Strike: $6.82 | $0.00 |
DisclosureSEC source: 0001437749-21-028836 · rdgdoc.xml · derivative · entry 5 Lask Alisa · CIK 0001767593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,062 Underlying: Common Stock · 7,062 shares Expires 2031-12-14 F4 · derivative.exercise_date: Represents options granted to the reporting person for her service on the Company's Board of Directors. This option vests as to 2,354 shares on each of 12/14/21, 12/14/22 and 12/14/23. Read SEC document |
| December 14, 2021 Filed Dec 17, 2021 02:17 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 4,582 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-028836 · rdgdoc.xml · nonDerivative · entry 1 Lask Alisa · CIK 0001767593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,725 F1 · shares: Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for her service on the Company's Board of Directors. These shares of restricted stock vest 6 months following the grant date. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:31 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (right to buy) · Derivative | 6,850 | $0.00 Strike: $8.06 | $0.00 |
DisclosureSEC source: 0000914190-21-000009 · edgar.xml · derivative · entry 4 Lask Alisa · CIK 0001767593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,850 Underlying: Common Stock · 6,850 shares Expires 2031-01-06 F4 · derivative.exercise_date: Represents options granted to the reporting person for her service on the Company's Board of Directors. This option vests as to 2,284 shares on 1/6/21 and as to 2,283 shares on each of 1/6/22 and 1/6/23. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:31 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 3,666 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000009 · edgar.xml · nonDerivative · entry 1 Lask Alisa · CIK 0001767593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,143 F1 · shares: Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for her service on the Company's Board of Directors. These shares of restricted stock vest 6 months following the grant date. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 22:13 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (right to buy) · Derivative | 5,568 | $0.00 Strike: $8.57 | $0.00 |
DisclosureSEC source: 0000914190-19-000508 · edgar.xml · derivative · entry 3 Lask Alisa · CIK 0001767593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,568 Underlying: Common Stock · 5,568 shares Expires 2029-12-16 F3 · derivative.exercise_date: On December 16, 2019, the Company granted an option to purchase 5,568 shares of common stock of the Company (the "Option") in respect of the service by Ms. Lask as a member of the Board of Directors of the Company. The Option was granted under the 2015 Plan. The Option vests as to 1,856 shares on each of 12/16/19, 12/16/20 and 12/16/21. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 22:13 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 3,227 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000508 · edgar.xml · nonDerivative · entry 1 Lask Alisa · CIK 0001767593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,477 F1 · shares: On December 16, 2019, the Company granted 3,227 shares of restricted stock of the Company (the "Restricted Stock") in lieu of cash fees payable to Ms. Lask in respect of her services as a member of the Board of Directors of the Company. The Restricted Stock was granted under the Company's 2015 Equity Incentive Plan (the "2015 Plan"). The Restricted Stock vests 6 months following the grant date. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 20:32 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 250 | $6.45 | $1,612.50 |
DisclosureSEC source: 0000914190-19-000377 · edgar.xml · nonDerivative · entry 1 Lask Alisa · CIK 0001767593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250 Read SEC document |
| February 08, 2019 Filed Feb 12, 2019 21:31 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (right to buy) · Derivative | 70,817 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0000914190-19-000023 · edgar.xml · derivative · entry 1 Lask Alisa · CIK 0001767593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,817 Underlying: Common Stock · 70,817 shares Expires 2029-02-08 F1 · derivative.exercise_date: On February 8, 2019, the Company granted to Ms. Lask an option to purchase 70,817 shares of common stock of the Company, of which one-third vested immediately upon the grant date, one-third will vest on the first anniversary of the grant date, and the remaining one-third will vest on the second anniversary of the grant date. Read SEC document |
| February 08, 2019 Filed May 2, 2019 20:05 UTC Amendment | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (right to buy) · Derivative | 86,546 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0000914190-19-000138 · edgar.xml · derivative · entry 1 Lask Alisa · CIK 0001767593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,546 Underlying: Common Stock · 86,546 shares Expires 2029-02-08 F1 · derivative.exercise_date: On February 8, 2019, the Company granted to Ms. Lask an option to purchase 86,546 shares of common stock of the Company, of which one-third vested immediately upon the grant date, one-third will vest on the first anniversary of the grant date, and the remaining one-third will vest on the second anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.